Pre-emptive broad-spectrum treatment for ventilator-associated pneumonia in high-risk patients
- 1.5k Downloads
Patients requiring mechanical ventilation (MV) for >48 h after major heart surgery (MHS) are at a high risk of acquiring ventilator-associated pneumonia (VAP) and tracheobronchitis (VAT). Most non-pharmacological interventions to prevent VAP in such patients are usually already implemented. The objective of this study was to evaluate the efficacy in preventing lower respiratory infections of antibiotics active against multidrug-resistant pathogens in this very high-risk population.
We performed a prospective randomized open-label study of MHS patients requiring MV for >48 h. Patients were randomly allocated to one of two groups: the intervention group, which received a 3-day course of linezolid and meropenem, and the control group, which received the standard of care. The main outcome was the development of VAP or VAT.
Overall, of the 78 patients included in the study, 40 were in the intervention group and 38 in the control group. Both groups were comparable. Data for the intervention and control groups respectively were as follows: VAP + VAT/1,000 days was 31.79 vs 64.78 (p = 0.03), median length of MV before the first episode of VAP or VAT 9 vs 4.5 days (p = 0.02). No significant differences were observed in median length of stay in the intensive care unit, median length of hospital stay, antibiotic use, Clostridium difficile infection, and overall mortality rate. We detected linezolid-resistant coagulase-negative and coagulase-positive staphylococci in the MHS intensive care unit after the study period.
A pre-emptive approach with broad-spectrum antibiotics may be effective in reducing the incidence and delaying the onset of VAP + VAT after MHS. The ecological consequences have to be carefully evaluated in future trials.
KeywordsVentilator-associated pneumonia Prevention Major heart surgery Pre-emptive treatment Intensive care Linezolid Meropenem
American Society of Anesthesiologists
Continuous aspiration of subglottic secretions
Clostridium difficile infection
Centers for Disease Control and Prevention
Daily defined doses
European System for Cardiac Operative Risk Evaluation
Intensive care unit
Lower respiratory tract infections
Major heart surgery
New York Heart Association
We thank Thomas O’Boyle for his help in the preparation of the English version of the manuscript and Cristina Fernández for the statistical analysis. Supported in part by Ciber de Enfermedades Respiratorias (CIBERES) and by the Rafael del Pino Foundation. This study was partially supported by grants from the Fondo de Investigación Sanitaria FIS PI070896, FIS PIO9/1257, and FISPI10/02869 (Instituto de Salud Carlos III).
Conflicts of interest
None of the authors have any conflicts of interest to declare.
- 7.Bekaert M, Timsit JF, Vansteelandt S, Depuydt P, Vesin A, Garrouste-Orgeas M, Decruyenaere J, Clec’h C, Azoulay E, Benoit D, Outcomerea Study Group (2011) Attributable mortality of ventilator-associated pneumonia: a reappraisal using causal analysis. Am J Respir Crit Care Med 184:1133–1139PubMedCrossRefGoogle Scholar
- 13.Padilla B, Bunsow E, Cercenado E, Marín M, Vicente T, Cantero M, Frías I, Bouza E (2011) Eradication of an outbreak of linezolid-resistant methicillin-resistant Staphylococcus aureus (LR–MRSA) in a post-surgical intensive care unit. In: 51st Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, Chicago, USAGoogle Scholar
- 32.Liberati A, D’Amico R, Pifferi S, Torri V, Brazzi L, Parmelli E (2009) Antibiotic prophylaxis to reduce respiratory tract infections and mortality in adults receiving intensive care. Cochrane Database Syst Rev (4): CD000022. doi: 10.1002/14651858.CD000022.pub3
- 33.Pileggi C, Bianco A, Flotta D, Nobile CG, Pavia M (2011) Prevention of ventilator-associated pneumonia, mortality and all intensive care unit acquired infections by topically applied antimicrobial or antiseptic agents: a meta-analysis of randomized controlled trials in intensive care units. Crit Care 15:R155PubMedCrossRefGoogle Scholar
- 34.Sanchez M, Cambronero JA, Lopez J, Cerda E, Rubio J, Gomez MA, Núnez A, Rogero S, Onoro JJ, Sacristán del Castillo JA (1998) Effectiveness and cost of selective decontamination of the digestive tract in critically ill intubated patients. A randomized, double-blind, placebo-controlled, multicenter trial. Am J Respir Crit Care Med 158:908–916CrossRefGoogle Scholar